Summary
53 / 100 · Bulios Score
What speaks for it
- It could repay all its net debt from 1.4 years of operating profit.
- It has been profitable 6 years in a row.
What to watch
- The share price is above the Bulios Fair Price.
- Earnings per share fell by 17% a year over the last 3 years.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 18.7 CHF for 1 CHF of yearly profit.
Valuation in detailIs it growing?
It is shrinkingRevenue (CHF)
Diluted EPS (CHF)
- Analyst estimate
Revenue fell by 0.7% a year over 5 years. Over the last 3 years it fell by 3.5% a year. Earnings per share fell by 17% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 CHF of revenue goes
- Cost of sales 39 CHF
- Sales and administration 53 CHF
- Taxes and other 1.9 CHF
- Net profit 6.3 CHF
Net profit, industry median (Medical - Instruments & Supplies) 8.4 CHF
Out of every 100 CHF of revenue, 6.3 CHF is left as net profit.
Profitability in detailIs it financially healthy?
MostlyRepaying all its debt would take 4.6 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, stretched- Yield
- 0.64%
- Paid out of profit
- 12%
- Raised in a row
- 1 year
You receive $0.36 per share a year. The payout takes a large part of its profit or free cash flow.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.